Boston, MA, March 3, 2021
HD LifeSciences today announced the expansion of its patent portfolio with the issuance of patent number US10,888,429 B2, Three-Dimensional Lattice Structures for Implants. The patent represents a key element of intellectual property related to an anisotropic load bearing, low stiffness, lattice structure, as well as the capability to tailor these properties to a specific purpose such as 3D printed titanium interbody cages.
Anisotropic lattice properties enable a method of reducing stress shielding of new bone growth in spinal fusion procedures. Similar to cancellous bone’s natural structure, this technology allows a lattice to exhibit mechanical properties varying with direction of force. For instance, bone in the spine is often stiffer in the rostral-caudal direction as compared with anterior-posterior. Matching elastic modulus in the direction defined by the loading of the spine is desirable because it allows the endplates of the adjacent vertebrae to move relative to one another, enabling loading of the new bone. HD’s durable and reliable lattice structure allows the sufficient strength of the interbody to provide stability during daily life, while allowing load sharing with newly forming bone. 
“This technology allows implants to further match physiological conditions as they vary with loading direction. Combined with the lattice’s internal volume curated to match the physiological dimensionality of bone substrates, this provides a strong tool for bone formation”, added Ian Helmar, Co-Founder and Vice President of Research & Development at HD LifeSciences, LLC.
————————————————
About HD LifeSciences
HD LifeSciences is a pioneer and leading innovator in 3D printed spinal interbody fusion implants and instrumentation. The company’s proprietary, biomimetic Soft Titanium™ technology clearly distinguishes their products in the $1.5B spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provide surgeons and their patients ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration – all features that lead to consistently strong fusion constructs and efficacious clinical experiences.
HD Lifesciences is located in Woburn, Massachusetts U.S.A
Contact: Patrick O’Donnell at patrick.odonnell@hdlifesciences.com
Website: www.hdlifesciences.com
